Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/20/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/20/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/20/2017
Women and Infants Hospital
mi
from
Providence, RI
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/20/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/20/2017
Greenville Health System Cancer Institute/Eastside
mi
from
Greenville, SC
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/20/2017
Greenville Health System Cancer Institute/Eastside
mi
from
Greenville, SC
Click here to add this to my saved trials
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/20/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/20/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer
Status: Enrolling
Updated:  9/20/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer
Status: Enrolling
Updated: 9/20/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer
Status: Enrolling
Updated:  9/20/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer
Status: Enrolling
Updated: 9/20/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of California - LAC Medical Center
mi
from
Los Angeles, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of California - LAC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Southern California, Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Southern California, Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
UC Irvine Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
UC Irvine Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
GRU Cancer Center - Georgia Regents University
mi
from
Augusta, GA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
GRU Cancer Center - Georgia Regents University
mi
from
Augusta, GA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
National Cancer Institute
mi
from
Bethesda, MD
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
National Cancer Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
The Long Islan Brain Tumor Center at Neurological Surgery P.C.
mi
from
Commack, NY
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
The Long Islan Brain Tumor Center at Neurological Surgery P.C.
mi
from
Commack, NY
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
Cleveland Clinic
mi
from
Cleveland, OH
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
Magee-Womens Hospital
mi
from
Pittsburgh, PA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
Magee-Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
Univeristy of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
Univeristy of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Colorado Cancer Center
mi
from
Aurora, CO
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
Northwestern University
mi
from
Chicago, IL
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of New Mexico
mi
from
Albuquerque, NM
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
A Multicenter, Open-Label, Crossover Trial to Assess Non-Inferiority of Dual Energy Contrast-Enhanced Digital Mammography (DE-CEDM) Compared to Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) for Identifying a Change in Patient Management in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  9/21/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
A Multicenter, Open-Label, Crossover Trial to Assess Non-Inferiority of Dual Energy Contrast-Enhanced Digital Mammography (DE-CEDM) Compared to Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) for Identifying a Change in Patient Management in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 9/21/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
A Multicenter, Open-Label, Crossover Trial to Assess Non-Inferiority of Dual Energy Contrast-Enhanced Digital Mammography (DE-CEDM) Compared to Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) for Identifying a Change in Patient Management in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  9/21/2017
AZ St-Jan Brugge AV
mi
from
Brugge,
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
A Multicenter, Open-Label, Crossover Trial to Assess Non-Inferiority of Dual Energy Contrast-Enhanced Digital Mammography (DE-CEDM) Compared to Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) for Identifying a Change in Patient Management in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 9/21/2017
AZ St-Jan Brugge AV
mi
from
Brugge,
Click here to add this to my saved trials
Hypofractionated Stereotactic Body Radiation Therapy (SBRT)
A Study of Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Using Continuous Real-time Evaluation of Prostate Motion
Status: Enrolling
Updated:  9/21/2017
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Hypofractionated Stereotactic Body Radiation Therapy (SBRT)
A Study of Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Using Continuous Real-time Evaluation of Prostate Motion
Status: Enrolling
Updated: 9/21/2017
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Hypofractionated Stereotactic Body Radiation Therapy (SBRT)
A Study of Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Using Continuous Real-time Evaluation of Prostate Motion
Status: Enrolling
Updated:  9/21/2017
The Radiological Associates of Sacremento
mi
from
Sacramento, CA
Hypofractionated Stereotactic Body Radiation Therapy (SBRT)
A Study of Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Using Continuous Real-time Evaluation of Prostate Motion
Status: Enrolling
Updated: 9/21/2017
The Radiological Associates of Sacremento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Children's Hospital of Alabama
mi
from
Birmingham, AL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Southern California Permanente Medical Group
mi
from
Downey, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Children's Hospital Central California
mi
from
Madera, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Children's Hospital Central California
mi
from
Madera, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Yale University
mi
from
New Haven, CT
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Lee Memorial Health System
mi
from
Fort Myers, FL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Lee Memorial Health System
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Univ of Illinois
mi
from
Chicago, IL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Univ of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Saint Jude Midwest Affiliate
mi
from
Peoria, IL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Saint Jude Midwest Affiliate
mi
from
Peoria, IL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials